Regulus Therapeutics, Inc
- Biotech or pharma, therapeutic R&D
Regulus aims to develop important, novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. Farabursen is in a P1b ADPKD patient study.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}